IL10 and myeloid sarcoma: The protective effect of excessive BAFF in MS is further confirmed by the observation that IFN-β therapy (first-line treatment for relapsing-remitting MS) elevates BAFF levels, favoring the expansion of IL-10-producing anti-inflammatory transitional B cells instead of inflammatory class-switched memory B cells [106].